HK1245673A1 - 甲基納曲酮的口服製劑和親脂鹽 - Google Patents

甲基納曲酮的口服製劑和親脂鹽

Info

Publication number
HK1245673A1
HK1245673A1 HK18105478.0A HK18105478A HK1245673A1 HK 1245673 A1 HK1245673 A1 HK 1245673A1 HK 18105478 A HK18105478 A HK 18105478A HK 1245673 A1 HK1245673 A1 HK 1245673A1
Authority
HK
Hong Kong
Prior art keywords
methylnaltrexone
oral formulations
lipophilic salts
lipophilic
salts
Prior art date
Application number
HK18105478.0A
Other languages
English (en)
Inventor
Syed M Shah
Christopher Richard Diorio
Eric C Ehrnsperger
Xu Meng
Shareffi Kadum A Al
Jonathan Marc Cohen
Original Assignee
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44148539&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1245673(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Llc filed Critical Wyeth Llc
Publication of HK1245673A1 publication Critical patent/HK1245673A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
    • C07D489/08—Oxygen atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HK18105478.0A 2010-03-11 2018-04-27 甲基納曲酮的口服製劑和親脂鹽 HK1245673A1 (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US31301810P 2010-03-11 2010-03-11

Publications (1)

Publication Number Publication Date
HK1245673A1 true HK1245673A1 (zh) 2018-08-31

Family

ID=44148539

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18105478.0A HK1245673A1 (zh) 2010-03-11 2018-04-27 甲基納曲酮的口服製劑和親脂鹽

Country Status (32)

Country Link
US (8) US8524276B2 (zh)
EP (2) EP2371357B1 (zh)
JP (4) JP6143409B2 (zh)
KR (2) KR101982482B1 (zh)
CN (2) CN102918039B (zh)
AR (1) AR080491A1 (zh)
AU (1) AU2011224275B2 (zh)
BR (1) BR112012022873B1 (zh)
CA (1) CA2789798C (zh)
CL (1) CL2012002192A1 (zh)
CO (1) CO6630134A2 (zh)
CR (1) CR20120476A (zh)
EA (1) EA029096B1 (zh)
EC (1) ECSP12012208A (zh)
ES (1) ES2623926T3 (zh)
GE (1) GEP201606550B (zh)
GT (1) GT201200247A (zh)
HK (1) HK1245673A1 (zh)
HU (1) HUE033133T2 (zh)
IL (1) IL221452A (zh)
MA (1) MA34146B1 (zh)
MX (2) MX349145B (zh)
MY (1) MY160727A (zh)
NZ (3) NZ702826A (zh)
PE (1) PE20130063A1 (zh)
PL (2) PL3178472T3 (zh)
SG (3) SG10201501821RA (zh)
TN (1) TN2012000392A1 (zh)
TW (2) TWI589293B (zh)
UA (2) UA123856C2 (zh)
WO (1) WO2011112816A1 (zh)
ZA (1) ZA201808498B (zh)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1615646T2 (sl) 2003-04-08 2022-11-30 Progenics Pharmaceuticals, Inc. Farmacevtske formulacije vsebujoče metilnatrekson
MX2009010550A (es) 2007-03-29 2009-12-14 Progenics Pharm Inc Formas de cristal de bromuro de (r)-n-metilnaltrexona y uso de las mismas.
US9061076B2 (en) 2007-05-25 2015-06-23 North Carolina State University Viral nanoparticle cell-targeted delivery platform
BR112012022873B1 (pt) 2010-03-11 2021-09-14 Wyeth Llc Composição farmacêutica para administração oral compreendendo brometo de metilnaltrexona e dodecil sulfato de sódio
US8939943B2 (en) 2011-01-26 2015-01-27 Kaleo, Inc. Medicament delivery device for administration of opioid antagonists including formulations for naloxone
US8627816B2 (en) 2011-02-28 2014-01-14 Intelliject, Inc. Medicament delivery device for administration of opioid antagonists including formulations for naloxone
BR112014014805A2 (pt) * 2011-12-19 2017-06-13 Salix Pharmaceuticals Ltd processos para tratamento e prevenção de constipação induzida por opióide que utilizam composições orais de metilnaltrexona
WO2015191686A1 (en) * 2014-06-10 2015-12-17 Salix Pharmaceuticals, Inc. Methods of administering methylnaltrexone
US10617686B2 (en) * 2014-07-08 2020-04-14 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
US9642848B2 (en) * 2014-07-08 2017-05-09 Insys Development Company, Inc. Sublingual naloxone spray
US11135155B2 (en) 2014-07-08 2021-10-05 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
US10722510B2 (en) * 2014-07-08 2020-07-28 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
US10441538B2 (en) * 2014-07-08 2019-10-15 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
CA3002137A1 (en) 2014-10-17 2016-04-21 Salix Pharmaceuticals, Inc. Use of methylnaltrexone to attenuate tumor progression
JP2022531685A (ja) * 2019-05-07 2022-07-08 バウシュ ヘルス アイルランド リミテッド メチルナルトレキソンの液体経口投与製剤
WO2020245214A1 (en) 2019-06-03 2020-12-10 Bausch Health Ireland Limited Use of methylnaltrexone and rifaximin for treatment of increased gut permeability or associated disorders
CA3177250A1 (en) 2020-05-02 2021-11-11 Bausch Health Ireland Limited Methods of reducing mortality risk in subjects suffering from an underlying disease or condition by administration of methylnaltrexone
WO2023031955A1 (en) * 2021-08-28 2023-03-09 Redasani Vijayendrakumar Virendrakumar Ji Oral pharmaceutical compositions of methylnaltrexone and salt thereof

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4176186A (en) 1978-07-28 1979-11-27 Boehringer Ingelheim Gmbh Quaternary derivatives of noroxymorphone which relieve intestinal immobility
US4861781A (en) 1986-03-07 1989-08-29 The University Of Chicago Quaternary derivatives of noroxymorphone which relieve nausea and emesis
US4719215A (en) 1986-03-07 1988-01-12 University Of Chicago Quaternary derivatives of noroxymorphone which relieve nausea and emesis
CA1297218C (en) 1986-03-14 1992-03-10 Edward David Weil Thermally stable diphosphonate-type flame retardant additive for plastics
US5102887A (en) 1989-02-17 1992-04-07 Arch Development Corporation Method for reducing emesis and nausea induced by the administration of an emesis causing agent
US5780012A (en) 1990-06-21 1998-07-14 Huland; Edith Method for reducing lung afflictions by inhalation of cytokine solutions
AU5171293A (en) 1992-10-14 1994-05-09 Regents Of The University Of Colorado, The Ion-pairing of drugs for improved efficacy and delivery
US5866154A (en) 1994-10-07 1999-02-02 The Dupont Merck Pharmaceutical Company Stabilized naloxone formulations
DE19651551C2 (de) 1996-12-11 2000-02-03 Klinge Co Chem Pharm Fab Opioidantagonisthaltige galenische Formulierung
SK282549B6 (sk) 1997-02-14 2002-10-08 G�decke Aktiengesellschaft Spôsob stabilizácie naloxonhydrochloridu
US6274591B1 (en) 1997-11-03 2001-08-14 Joseph F. Foss Use of methylnaltrexone and related compounds
EP0913152B1 (de) 1997-11-03 2001-12-19 Stada Arzneimittel Ag Stabilisiertes Kombinationsarzneimittel enthaltend Naloxone und ein Opiatanalgetikum
US6559158B1 (en) 1997-11-03 2003-05-06 Ur Labs, Inc. Use of methylnaltrexone and related compounds to treat chronic opioid use side affects
US20030158220A1 (en) 1997-11-03 2003-08-21 Foss Joseph F. Use of methylnaltrexone and related compounds to treat chronic opioid use side effects
US5972954A (en) 1997-11-03 1999-10-26 Arch Development Corporation Use of methylnaltrexone and related compounds
GB0100115D0 (en) 2001-01-04 2001-02-14 Alchemia Pty Ltd Delivery systems
EP1387673B1 (en) * 2001-05-11 2010-12-29 Endo Pharmaceuticals Inc. Abuse-resistant controlled-release opioid dosage form
EP1404323B1 (en) 2001-06-05 2009-10-28 The University of Chicago Use of methylnaltrexone to treat immune suppression
CA2463938C (en) 2001-10-18 2011-08-09 Nektar Therapeutics Al, Corporation Polymer conjugates of opioid antagonists
CN1596254A (zh) 2001-11-29 2005-03-16 先灵公司 含有增加量的旋转异构体的药物活性盐的组合物的制备方法
CN1652752A (zh) 2002-03-14 2005-08-10 欧罗赛铁克股份有限公司 盐酸纳曲酮组合物
US20030191147A1 (en) 2002-04-09 2003-10-09 Barry Sherman Opioid antagonist compositions and dosage forms
MXPA05010821A (es) 2003-04-08 2006-03-30 Progenics Pharm Inc Terapia de combinacion para constipacion que comprende un laxante y un antagonista opioide periferico.
US20050004155A1 (en) 2003-04-08 2005-01-06 Boyd Thomas A. Use of methylnaltrexone to treat irritable bowel syndrome
SI1615646T2 (sl) 2003-04-08 2022-11-30 Progenics Pharmaceuticals, Inc. Farmacevtske formulacije vsebujoče metilnatrekson
WO2005009356A2 (en) * 2003-07-15 2005-02-03 Pr Pharmaceuticals, Inc. Method for the preparation of controlled release formulations
US8946262B2 (en) 2003-12-04 2015-02-03 Adolor Corporation Methods of preventing and treating gastrointestinal dysfunction
NZ547557A (en) 2003-12-19 2010-07-30 Schering Corp Pharmaceutical compositions containing a cationic A2A receptor antagonist
MXPA06007512A (es) * 2003-12-31 2006-08-31 Pfizer Prod Inc Composiciones solidas farmaceuticas estabilizadas de farmacos de baja solubilidad, poloxameros y polimeros estabilizadores.
CN1294728C (zh) 2004-08-05 2007-01-10 华为技术有限公司 边缘路由器提供服务质量保证的方法及***
CN101061073A (zh) 2004-09-30 2007-10-24 贝克顿·迪金森公司 减少或消除玻璃容器中残余物的方法以及根据该方法制成的玻璃容器
US20060177380A1 (en) * 2004-11-24 2006-08-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
AR057035A1 (es) * 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
TWI489984B (zh) * 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
WO2008021394A2 (en) * 2006-08-15 2008-02-21 Theraquest Biosciences, Llc Pharmaceutical formulations of cannabinoids and method of use
ATE553787T1 (de) * 2006-08-16 2012-05-15 Novartis Ag Vorübergehende lichtbleichung von farbigen linsenpflegelösungen
EP2073797A2 (en) * 2006-10-11 2009-07-01 Alpharma, Inc. Pharmaceutical compositions
TW200843802A (en) 2007-02-09 2008-11-16 Drugtech Corp Compositions for improving gastrointestinal nutrient and drug absorption
PT2139890E (pt) * 2007-03-29 2014-09-03 Wyeth Llc Antagonistas do receptor opióide periférico e respectivas utilizações
MX2009010550A (es) * 2007-03-29 2009-12-14 Progenics Pharm Inc Formas de cristal de bromuro de (r)-n-metilnaltrexona y uso de las mismas.
JP5178064B2 (ja) * 2007-06-27 2013-04-10 富士フイルム株式会社 金属表面粗化層を有する金属層積層体及びその製造方法
BRPI0912219A2 (pt) * 2008-05-07 2015-10-06 Nektar Therapeutics método, forma de dose unitária, e, antagonista de opióide oralmente administrável que atua perifericamente.
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
JP5525247B2 (ja) * 2009-08-04 2014-06-18 株式会社神戸製鋼所 高強度で曲げ加工性に優れた銅合金
BR112012022873B1 (pt) 2010-03-11 2021-09-14 Wyeth Llc Composição farmacêutica para administração oral compreendendo brometo de metilnaltrexona e dodecil sulfato de sódio
TW201235609A (en) * 2010-07-13 2012-09-01 Koninkl Philips Electronics Nv Low cost mounting of LEDs in TL-retrofit tubes

Also Published As

Publication number Publication date
HUE033133T2 (en) 2017-11-28
SG10201501821RA (en) 2015-05-28
US20190314365A1 (en) 2019-10-17
KR101913102B1 (ko) 2018-10-31
EA201270741A1 (ru) 2013-02-28
MX2012009125A (es) 2012-09-07
NZ702826A (en) 2016-08-26
PE20130063A1 (es) 2013-02-11
IL221452A0 (en) 2012-10-31
CN107308125A (zh) 2017-11-03
PL2371357T3 (pl) 2017-09-29
US10376505B2 (en) 2019-08-13
NZ601595A (en) 2015-01-30
TW201141479A (en) 2011-12-01
US20200121673A1 (en) 2020-04-23
EP2371357B1 (en) 2017-02-01
JP6647368B2 (ja) 2020-02-14
CL2012002192A1 (es) 2012-09-28
WO2011112816A1 (en) 2011-09-15
KR20130010900A (ko) 2013-01-29
UA123856C2 (uk) 2021-06-16
MX368805B (es) 2019-10-17
EA029096B1 (ru) 2018-02-28
MY160727A (en) 2017-03-15
EP3178472A1 (en) 2017-06-14
JP2019034958A (ja) 2019-03-07
TW201622724A (zh) 2016-07-01
US20190117646A1 (en) 2019-04-25
US20160206612A1 (en) 2016-07-21
ECSP12012208A (es) 2015-03-31
KR20180118260A (ko) 2018-10-30
PL3178472T3 (pl) 2022-02-14
TWI605814B (zh) 2017-11-21
US20120070495A1 (en) 2012-03-22
MX349145B (es) 2017-07-14
BR112012022873A2 (pt) 2016-08-30
US20190117645A1 (en) 2019-04-25
CR20120476A (es) 2012-11-30
CA2789798C (en) 2020-09-22
AU2011224275B2 (en) 2015-10-01
CA2789798A1 (en) 2011-09-15
JP2016029054A (ja) 2016-03-03
SG183133A1 (en) 2012-09-27
EP3178472B1 (en) 2021-10-27
NZ703564A (en) 2016-08-26
KR101982482B1 (ko) 2019-05-27
US8956651B2 (en) 2015-02-17
TN2012000392A1 (en) 2014-01-30
JP2017206553A (ja) 2017-11-24
UA111717C2 (uk) 2016-06-10
US20130330407A1 (en) 2013-12-12
US8524276B2 (en) 2013-09-03
US9314461B2 (en) 2016-04-19
US20140249171A1 (en) 2014-09-04
TWI589293B (zh) 2017-07-01
ZA201808498B (en) 2019-08-28
JP6429955B2 (ja) 2018-11-28
GEP201606550B (en) 2016-10-10
AU2011224275A1 (en) 2012-08-23
IL221452A (en) 2017-07-31
MA34146B1 (fr) 2013-04-03
BR112012022873B1 (pt) 2021-09-14
US10307417B2 (en) 2019-06-04
CO6630134A2 (es) 2013-03-01
EP2371357A1 (en) 2011-10-05
JP2011190259A (ja) 2011-09-29
CN102918039B (zh) 2017-06-09
CN107308125B (zh) 2021-07-16
GT201200247A (es) 2013-09-11
AR080491A1 (es) 2012-04-11
CN102918039A (zh) 2013-02-06
ES2623926T3 (es) 2017-07-12
JP6143409B2 (ja) 2017-06-07
SG10201606618PA (en) 2016-09-29
US10507206B2 (en) 2019-12-17

Similar Documents

Publication Publication Date Title
ZA201808498B (en) Oral formulations and lipophilic salts of methylnaltrexone
EP2448406A4 (en) ORAL PHARMACEUTICAL COMPOSITIONS OF 3-HYDROXY-N-METHYLMORPHINAN WITH DELAYED RELEASE AND METHOD OF USE THEREOF
HK1183802A1 (zh) 治療性口腔組合物
IL222919A0 (en) Alcohol - resistant oral pharmaceutical form
EP2461691A4 (en) THERAPEUTIC VITAMIN D SUNSCREEN FORMULATIONS AND METHOD OF USE THEREOF
EP2548859A4 (en) PREPARATION OF METHYL-D3-AMINE AND SALTS THEREOF
HK1183228A1 (zh) 口服藥物治療方法和組合物
ZA201205441B (en) Dental strip for administration of oral treatment
ZA201300160B (en) Formulations including amiodarone and salts thereof and methods of their manufacture and use
EP2714024A4 (en) ORAL FORMULATIONS FROM ANTIOXIDANTS FACED ON MITOCHONDRIA AND THE PREPARATION AND USE THEREOF
IL223311A0 (en) Oral dosage forms of bendamustine
RS61362B1 (sr) Farmaceutske formulacije loratadina za inkapsulaciju i njihove kombinacije
IL224191A (en) Compositions of vitamin d and cmc epi-14 analogues
ZA201207945B (en) Salts of dexlansoprazole and their preparation
EP2780029A4 (en) ORAL LEPTIN FORMULATIONS AND USES THEREOF
SI2654723T1 (sl) Trdne farmacevtske dozirna oblike, ki obsegajo tadalafil in metode za njihovo pripravo
EP2419085A4 (en) IMPROVED DEVICES FOR ORAL MEDICINAL PRODUCTS AND MEDICINAL PRODUCTS
EP2529755A4 (en) PHARMACEUTICAL COMPOSITION AND PREPARATION THEREFOR FOR ORAL ADMINISTRATION
TWM390131U (en) Improved structure of dental scaler
GB201018760D0 (en) An oral dosage form
GB0906003D0 (en) Oral drug formulation
PL390434A1 (pl) Preparat leczniczy
TWM388322U (en) Improved structure of dental handpiece
GB201012047D0 (en) Pharmaceutical formulations
GB201012046D0 (en) Pharmaceutical formulations